Change language to Arabic Change language to Chinese (Simplified) Change language to Dutch Change language to English Change language to French Change language to German Change language to Italian Change language to Japanese Change language to Portuguese Change language to Russian Change language to Spanish

News | 3 min read

Phlow launches key essential medicines to leading children’s hospitals to help alleviate impact of shortages

March 9, 2022

Children’s Hospital Coalition (CHC) encourages more children’s hospitals to join and tackle the shortage crisis

RICHMOND, Va., March 9, 2022 — Phlow, a U.S.-based, public benefit impact-driven pharmaceutical company, announced the launch of key essential medicines, sequentially over the coming quarter, for the Children’s Hospital Coalition™ (CHC), a first-in-kind coalition of leading pediatric institutions. The availability of these medications is an important first step demonstrating Phlow’s commitment to CHC members to provide a reliable and affordable supply of high-quality essential medicines to help prevent pediatric drug shortages. “Essential medicines” are defined as those that satisfy the priority health care needs of the American population to sustain life and conquer disease.

“We have worked closely with the CHC to identify critical essential medicines necessary to treat pediatric patients that are either at-risk of, or currently in, shortage,” said Dr. Eric Edwards, CEO of Phlow. “We are thrilled to have an initial portfolio of products going into the hands of children’s hospitals to start the process of bringing certainty and resiliency to the supply chain and we will continue to work with the hospital members to mitigate the impact of shortages.”

Children’s hospitals serve an especially vulnerable population and may struggle to access needed medicines, forcing patients onto alternative therapies or delaying needed treatments. The injectable medications being launched, manufactured through an alliance with Fresenius Kabi USA, include Furosemide Injection, USP, a diuretic which treats fluid retention and swelling; Dexamethasone Sodium Phosphate Injection, USP, a corticosteroid to treat disorders of many organ systems; Heparin Sodium Injection, USP, a blood thinner to prevent and treat blood clots; and Rocuronium Bromide Injection, which is typically given before general anesthesia in preparing for surgery and used to relax the muscles.

“As a founding member of this coalition, I’m excited to see our vision being realized – strengthening the essential medicine supply chain and delivering key pediatric medicines effectively and efficiently to children’s hospitals across the country,” said Dr. Kurt Newman, president and CEO of Children’s National Hospital. “This coalition demonstrates the power of public-private partnerships and how they can effect positive change. I invite more children’s hospitals to join this innovative group addressing pediatric medication shortages.”

The founding members of the CHC, including Phlow, recognize that essential medicine supply is a critical problem in the U.S. and welcome new children’s hospital members to join in this bold initiative.

Read the full story here.